• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem reports positive data for t:slim X2 insulin pump with Control-IQ technology

June 6, 2022 By Sean Whooley

Tandem Diabetes Care tslim_X2_Insulin_Pump_Front_View_Control-IQ_RGB
Image from Tandem Diabetes

Tandem Diabetes Care (Nasdaq:TNDM) announced today that real-world data supports its t:slim X2 insulin pump with Control-IQ technology.

Data from the ongoing real-world Control-IQ observational (CLIO) study demonstrating immediate and sustained benefits in a diverse cohort of participants was presented at the American Diabetes Association (ADA) 82nd Scientific Sessions in New Orleans.

“Our Control-IQ technology continues to be a great equalizer for people with insulin-intensive diabetes, as we consistently see positive clinical and quality-of-life improvement with its use, regardless of age, ethnicity, or prior therapy,” Tandem VP and Medical Director Dr. Jordan Pinsker said in a news release. “This evidence increases our motivation to bring new advances in technology to benefit people living with diabetes worldwide.”

An analysis of a multi-ethnic adult cohort consisting of 1,306 participants with type 1 diabetes demonstrated significant improvements in diabetes-specific quality of life, satisfaction with insulin delivery device, and reduction in diabetes-related burden over 12 months with Control-IQ technology. All ethnic cohorts experienced Psychosocial benefits, Tandem said, while all participants using the system also noted significantly improved quality of sleep.

Tandem also shared data from an analysis of 1,045 adult CLIO patients that assessed relationships between ethnicity, baseline HbA1c, Glucose Management Indicator (GMI) and sensor time in range. The cohort included Asian, Black/African American, White, and Hispanic/Latino/Spanish participants and GMI at study end reflected glycemic improvements for all participants, with Black/African American participants demonstrating a clinically relevant 0.7% overall reduction.

Real-world evidence from a study of baseline HbA1c and GMI derived from sensor data in 1,107 adults using Control-IQ technology for 12 consecutive months demonstrated significant glycemic improvements, regardless of prior therapy modality.

Multiple daily injection users with relatively high HbA1c values initiating Control-IQ technology showed dramatic and sustained glycemic improvements, Tandem said, while previous pump users also experienced immediate and sustained imporvements.

“Demonstrating that our technology benefits ethnically diverse groups, irrespective of previous therapy modality, is critical to fulfilling our mission to improve the lives of people living with diabetes worldwide,” Tandem VP of Behavioral Sciences Steph Habif said. “As a global leader in insulin therapy management, we strive to provide diabetes care solutions that work equally well across all people living with diabetes, and the data presented at this conference is evidence of our success toward this goal.”

Filed Under: Auto-injectors, Big Data, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Lyra Therapeutics appoints new chief medical officer
  • FDA lifts hold on Vertex’s insulin-producing cell therapy for diabetes
  • Retractable Technologies declares dividends
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • West Pharmaceutical Services debuts new needle syringe system

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS